Cyanopyrazine is a heterocyclic compound with a fused pyrazine ring system containing a cyano group. It has been studied for its potential applications in organic electronics, particularly as an electron-accepting material in organic solar cells. Cyanopyrazine derivatives have shown promising results in enhancing the efficiency of organic solar cells due to their strong electron-withdrawing properties. The synthesis of cyanopyrazine typically involves the reaction of pyrazine with cyanogen chloride or cyanogen bromide. Research on cyanopyrazine focuses on understanding its electronic properties, exploring its use in various organic electronic devices, and developing synthetic strategies for preparing its derivatives.'
cyanopyrazine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 73172 |
| CHEMBL ID | 4553837 |
| CHEBI ID | 3982 |
| SCHEMBL ID | 151926 |
| MeSH ID | M0182601 |
| Synonym |
|---|
| pyrazinecarbonitrile- |
| NCIOPEN2_000422 |
| nsc-72371 |
| nsc72371 |
| C02018 |
| 19847-12-2 |
| cyanopyrazine |
| 2-cyanopyrazine |
| nsc166137 |
| nsc-166137 |
| pyrazinenitrile |
| 2-pyrazinecarbonitrile |
| pyrazinonitrile |
| pyrazinecarbonitrile |
| pyrazine-2-carbonitrile |
| pmsvvusipkhumt-uhfffaoysa- |
| inchi=1/c5h3n3/c6-3-5-4-7-1-2-8-5/h1-2,4h |
| pyrazinecarbonitrile, 99% |
| CHEBI:3982 |
| STL163427 |
| AKOS005716621 |
| nsc 166137 |
| unii-74cp756b49 |
| einecs 243-369-5 |
| 74cp756b49 , |
| bdbm92861 |
| pnca inhibitor, 6 |
| FT-0612119 |
| AB02102 |
| SCHEMBL151926 |
| AM81383 |
| DTXSID9066540 |
| W-107669 |
| STR01734 |
| PS-9305 |
| mfcd00049361 |
| CS-W008971 |
| F0001-0707 |
| Z448103898 |
| Q27106278 |
| pyrazinyl cyanide |
| pyrazinamide impurity b [ep impurity] |
| EN300-44258 |
| CHEMBL4553837 |
| HY-Y0131 |
| Class | Description |
|---|---|
| pyrazines | |
| nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1637722 | Glutathione reactivity assessed as half life at 250 uM up to 72 hrs by HPLC-MS or NMR analysis | 2019 | MedChemComm, Feb-01, Volume: 10, Issue:2 | Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors. |
| AID1637721 | Glutathione reactivity assessed as thiol reactivity rate constant at 250 uM up to 72 hrs by HPLC-MS or NMR analysis | 2019 | MedChemComm, Feb-01, Volume: 10, Issue:2 | Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors. |
| AID1637723 | Stability of the compound assessed as half life for degradation | 2019 | MedChemComm, Feb-01, Volume: 10, Issue:2 | Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors. |
| AID1799845 | Enzyme Assay from Article 10.1021/bi1011157: \\Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.\\ | 2010 | Biochemistry, Nov-09, Volume: 49, Issue:44 | Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||